CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS

Size: px
Start display at page:

Download "CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS"

Transcription

1 CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS PHM153A January 2014 Usha Nagavarapu Project Analyst ISBN: BCC Research 49 Walnut Park, Building 2 Wellesley, MA USA (toll-free within the USA), or (+1) information@bccresearch.com

2 TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2 STUDY GOALS AND OBJECTIVES 2 REASONS FOR DOING THIS STUDY 2 INTENDED AUDIENCE 2 SCOPE OF THE STUDY 3 METHODOLOGY 3 INFORMATION SOURCES 4 ABOUT THE AUTHOR 4 RELATED BCC RESEARCH REPORTS 4 BCC RESEARCH ONLINE SERVICES 4 DISCLAIMER 5 CHAPTER 2 SUMMARY 7 SUMMARY TABLE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, THROUGH 2018 ($ MILLIONS) SUMMARY FIGURE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, ($ MILLIONS) 8 8 CHAPTER 3 CIRCULATING TUMOR CELLS 10 CANCER 10 RECENT ADVANCES IN TECHNOLOGY 10 INVASIVE POWER 11 CIRCULATING TUMOR CELL 11 PHENOTYPIC CHARACTERISTICS 11 CTC CLUSTERS 12 CTC DETECTION 12 CANCER STEM CELLS (CSC) 13 TABLE 1 CATEGORIES OF STEM CELLS 14 TABLE 2 PRODUCT CATEGORIES 15 CIRCULATING TUMOR CELLS - POTENTIAL USES 15 TABLE 3 KEY FACTORS OF CTC S 16 What Are Circulating Tumor Cells? 16 Biology and Characteristics of CTCs 17 TABLE 4 CIRCULATING TUMOR CELLS - FEATURES 18 PROLIFERATIVE ACTIVITY 18 EPITHELIAL MARKER GENES ON CIRCULATING TUMOR CELLS 19 CTCs as Biomarkers 20 Biomarker Qualification Program 21 Epithelial to Mesenchymal Transition 21 CIRCULATING TUMOR CELLS AND STEM CELL-LIKE PHENOTYPE 22 CTCS AND PRIMARY TUMOR CELLS: COMPARISON 22 METASTASIS 23 The Metastatic Process 23 FUTURE DIRECTIONS 24 TABLE 5 METASTATIC CASCADE 24 METASTATIC DEVELOPMENT IN CANCER PATIENTS 25

3 CIRCULATING TUMOR CELL MIGRATION 25 IMPORTANT MARKERS OF DISTANT METASTASIS 25 CIRCULATING TUMOR CELL DETECTION 25 TABLE 6 EPCAM-BASED ASSAYS 26 CHALLENGES FOR DETECTION 26 THE CLINICAL APPLICATION OF CIRCULATING TUMOR DNA 27 CIRCULATING TUMOR CELLS AS PREDICTOR OF RESPONSE TO THERAPY 27 MEASUREMENT OF CTCS - APPLICATIONS 28 CONCLUSION 28 TABLE 7 CTC DETECTION - ADVANTAGES 29 CHAPTER 4 INCIDENCE OF CANCER 31 WORLDWIDE GROWTH IN THE INCIDENCE OF CANCER 31 TABLE 8 CANCER - KEY FACTS 32 CAUSES OF CANCER 32 TABLE 9 CANCER CAUSES 33 RISK FACTORS FOR CANCERS 33 BURDEN OF CANCER 33 AVOIDING RISK FACTORS 33 TABLE 10 CANCER CAUSING FACTORS 34 Prevention Strategies 34 EARLY DETECTION 34 Early Diagnosis 34 Screening 34 TABLE 11 CANCER SCREENING METHODS 35 TREATMENT 35 Treatment of Early-Detectable Cancers 35 Treatment of Other Cancers with Potential for Cure 35 PALLIATIVE CARE 35 Palliative Care Strategies 36 WORLD HEALTH ORGANIZATION RESPONSE 36 TABLE 12 NONCOMMUNICABLE DISEASES ACTION PLAN 36 WORLD CANCER STATISTICS 36 TABLE 13 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS) 37 FIGURE 1 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS) 37 TABLE 14 ESTIMATED GLOBAL CANCER INCIDENCE, 2008 (THOUSANDS) 38 CANCER AND THE GLOBAL IMPACT 38 Prevalence 39 Global Patterns 39 THE FUTURE OF CANCER 40 TABLE 15 INCREASE IN CANCER BURDEN - FACTORS 41 Common Types of Cancer 42 TABLE 16 THE MAIN TYPES OF CANCER AND ASSOCIATED MORTALITY 43 TABLE 17 GENERAL GLOBAL CANCER INCIDENCE BY TYPE 43 TABLE 18 GLOBAL INCIDENCE OF CANCER BY TYPE, 2008 (THOUSANDS/%) 44 Global Incidence in Men 45 TABLE 19 CANCER INCIDENCE IN MEN, 2008 (THOUSANDS/%) 45

4 Global Incidence in Women 46 TABLE 20 CANCER INCIDENCE IN WOMEN, 2008 (THOUSANDS/%) 46 Developed Countries 47 TABLE 21 GLOBAL INCIDENCE OF CANCER IN DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000, 2008 Men 48 TABLE 22 GLOBAL INCIDENCE OF CANCER IN MEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008 Incidence in Women 49 TABLE 23 GLOBAL INCIDENCE OF CANCER IN WOMEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008 UNITED STATES CANCER INCIDENCE 50 TABLE 24 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, FIGURE 2 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, BREAST CANCER 51 TABLE 25 GLOBAL BREAST CANCER FACTS 51 TABLE 26 BREAST CANCER IN THE UNITED STATES 52 COLORECTAL CANCER 53 TABLE 27 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN MEN, 2008 TABLE 28 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN WOMEN, 2008 U.S. Incidence 55 TABLE 29 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, FIGURE 3 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, PROSTATE CANCER 56 TABLE 30 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF PROSTATE CANCER, 2008 Westernization Trends 57 TABLE 31 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS) FIGURE 4 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS) Prostate Cancer Mortality 60 TABLE 32 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008 FIGURE 5 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008 Prostate Cancer a Burden Globally 61 TABLE 33 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, FIGURE 6 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER Prostate Cancer and the U.S. 63 TABLE 34 PROSTATE CANCER CASES AND DEATHS IN THE U.S FIGURE 7 PROSTATE CANCER CASES AND DEATHS IN THE U.S., TABLE 35 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S.,

5 FIGURE 8 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., TABLE 36 PROSTATE CANCER INCIDENCE RATES IN THE U.S. BY RACE, (PER 100,000 MEN) TABLE 37 ESTIMATED PROSTATE CANCER CASES IN THE U S., 2020 AND 2030 FIGURE 9 ESTIMATED PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030 Prostate Cancer Mortality Rates in the U.S. 66 TABLE 38 MORTALITY RATES BY RACE IN U.S., Prostate Cancer in Canada 67 TABLE 39 ESTIMATED PROSTATE CANCER IN CANADA, Prostate Cancer in Europe 67 TABLE 40 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION, 2008 FIGURE 10 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008 Prostate Cancer in the United Kingdom 69 TABLE 41 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION) FIGURE 11 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION) Prostate Cancer in Asia 71 CONCLUSIONS CHAPTER 5 TECHNOLOGIES 74 FINDING CIRCULATING TUMOR CELLS 74 TABLE 42 POTENTIAL APPLICATIONS OF CTC-BASED DIAGNOSTICS 74 CURRENT CTC DETECTION AND ISOLATION METHODS 75 NEW TECHNOLOGIES FOR THE DETECTION 75 CANCER PROGNOSIS 76 Carcinoma - CTC and the Metastatic Cascade 77 How many CTCs? 77 The Biological Characteristics of CTC 77 TABLE 43 CLINICAL RELEVANCE OF CTC 78 Cancer Dissemination 78 CTC DETECTION TECHNIQUES - REQUIREMENTS 78 TABLE 44 CTC ENRICHMENT METHODS 78 ENRICHMENT METHODS 79 TABLE 45 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ENRICHMENT 80 Morphology-Based Enrichment Methods 80 Cell Separation Based on Density Gradient Centrifugation 80 Size-Based Cell Enrichment by Filtration 81 Immunomagnetic Separation Techniques 81 The RosetteSep-Applied Imaging Rare Event (RARE) Method 82 MagSweeper 83 DETECTION METHODS 83

6 TABLE 46 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ANALYSIS 84 Immunocytochemical Approaches 84 Fiber-Optic Array Scanning Technology 85 Laser Scanning Cytometer 85 Multiphoton Intravital Flow Cytometry 85 COMBINED ENRICHMENT AND DETECTION METHODS 85 TABLE 47 ENUMERATION TECHNIQUES 86 CellSearch System 86 Microfluidic Devices 87 Microfluidic Chips 87 EPISPOT 88 AdnaTest 88 TelomeScan 89 CTC Chip 89 TABLE 48 FUNCTIONAL ASSAYS 90 NUCLEIC ACID-BASED METHODS 91 Limitations 92 Flow Cytometry 92 Image-Based Approaches 93 Reverse-Transcriptase PCR 93 CLINICAL TESTING 94 CTC Analysis in Cancer Patients 94 CTC Analysis in Patients with Metastatic Disease 95 SUMMARY 96 TABLE 49 KEY FACTS ABOUT CIRCULATING TUMOR CELLS 97 NEW EMERGING TECHNOLOGIES 97 TABLE 50 MICRO-COUNT FEATURES A NEW TECHNOLOGY 98 Herringbone-Chip (HB-Chip) 98 Future Directions 99 CHAPTER 6 CIRCULATING TUMOR CELLS AND CANCER DIAGNOSTICS 101 TABLE 51 CTC ASSAY PRE-ANALYTICAL VALIDATION CONSIDERATIONS 102 TABLE 52 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS 102 TABLE 53 CTC ASSAY POST-ANALYTICAL VALIDATION CONSIDERATIONS 103 USE OF CTC'S FOR DIAGNOSIS 103 TABLE 54 CURRENT ENRICHMENT ASSAYS FOR CTCS 105 TABLE 55 CTC ENUMERATION ASSAYS 108 CURRENT METHODS AND APPLICATIONS 110 CTC Chip 110 TABLE 56 CHARACTERIZATION ASSAYS FOR CTCS 111 IVD Diagnostics 112 TABLE 57 KEY FEATURES-IVD CTC TESTS 112 TABLE 58 TUMOR TYPES: PROJECTED NEW CASES AND ESTIMATED DEATHS, FIGURE 12 TUMOR TYPES - PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010 IVDiagnostics Customized Aptamer Selection Service 114 IVDiagnostics CTC Capture 114 IVDiagnostics CTC Human Genetics

7 Biocept 114 CIRCULATING TUMOR CELLS IN PROSTATE CANCER: CASE STUDIES 114 TABLE 59 PROSTATE CANCER DIAGNOSIS AND ROLE OF CTC'S 115 CTC IN COMPANION DIAGNOSTICS 115 TABLE 60 CURRENT DIAGNOSTIC METHODS 115 ApoCell 116 TABLE 61 APOSTREAM KEY FEATURES 116 ApoStream CTC Imaging 116 Clarient Launches Biocept's OncoCEE-BR Test 117 Canopus Bioscience 117 TABLE 62 CANOPUS BIOSCIENCE TECHNOLOGY - BENEFITS 118 Ikonisys 118 TABLE 63 CELLOPTICS' CANCER APPLICATION 118 Technique 119 TABLE 64 CELLOPTICS' KEY FEATURES - ENRICHMENT 119 TABLE 65 CELLOPTICS' KEY FEATURES - LABELING 119 TABLE 66 CELLOPTICS' KEY FEATURES - DETECTION 120 RAREcells Diagnostics 120 TABLE 67 ISET TEST - SPECIFICATIONS 120 NEWER TECHNOLOGIES IN DEVELOPMENT 121 OriGene Technologies 121 Protein Microarray and Its Application 121 Viator Technologies 121 Photoacoustic Detection and Capture of CTCs 121 Micro Technologies 121 Interrogate Signaling in Single Cells 121 NanoVelcro 122 Embedded Microchips 122 MOLECULAR ANALYSES OF CTC 122 The Ephesia Magnetic Arrays Technology 122 New "Biopsy in a Blood Test" 122 CONCLUSIONS 124 CHAPTER 7 CTCS IN CLINICAL TRIALS 126 CTC DIAGNOSTICS 126 CIRCULATING TUMOR CELL TECHNOLOGY 126 POTENTIAL THERAPEUTIC USES OF CIRCULATING TUMOR CELLS 127 CHALLENGES IN THE DETECTION OF CIRCULATING TUMOR CELLS 128 CTC'S AS CLINICAL BIOMARKERS 129 PCR-BASED MARKERS 130 Carcinoma Cells 130 CIRCULATING TUMOR CELLS IN CANCER - CURRENT STATUS 130 Breast Cancer 130 STIC CTC METABREAST (France) 131 SWOG 0500 (USA) 132 CirCe01 (France) 132 Treat CTC (Europe) 133

8 DETECT III (Germany) 134 PROGNOSTIC AND PREDICTIVE VALUE OF CIRCULATING TUMOR CELLS (CTC'S) Breast Cancer 135 Pancreatic Cancer 136 Lung Cancer 137 CTC'S IN CLINICAL CANCER MANAGEMENT 137 TABLE 68 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT 137 Clinical Impact of CTCs 138 EXISTING TECHNOLOGIES IN CLINICAL TRIALS 138 Cell Search and AdnaTest - Comparision 138 Size- and Biomechanical Properties-Based Isolation 140 CLINICAL STUDIES USING CELLSEARCH TECHNOLOGY 141 TABLE 69 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT 142 APPROVALS 142 RECENT STUDIES 143 Tumor Cell (CTC) Enumeration Using Cellsearch 143 CELLSEARCH IN CHINA 144 VERIDEX AND MASSACHUSETTS GENERAL HOSPITAL COLLABORATION 145 POSSIBLE USE OF CTC'S AND DTC'S AS NEW BIOMARKERS 146 EPISPOT 147 CLINCIAL APPLICATIONS 147 TABLE 70 EPISPOT: CLINICAL TRIALS FOR DETECTION OF CTC S 148 Descriptions of Clinical Trials 148 NCT Trial 148 NCT Trial 148 NCT Trial 148 TABLE 71 OUTCOME MEASUREMENTS NCT TRIAL 149 ApoCell 149 ApoCell and Transgenomic Present Results of Lung Cancer Research Study ApoCell's CTC Capture Technology Detects and Recovers Deadly Liver Cancer Cells Nektar's Ongoing Phase 3 BEACON Study 150 APPLICATIONS 151 Application of ictc Detection and Culture in Personalized Cancer Management Stony Brook University Medical Center 151 Microfluidic Sorting of Blood Cells for Cellular and Molecular Analysis 152 Cancer Sample Preparation with Micromachined Magnetic Sifter and Nanoparticles Stanford Center for Magnetic Nanotechnology 152 The Scripps Research Institute: The Fluid Phase of Solid Tumors 152 ApoCell - Utilization of Dielectrophoresis for Antigen-Independent CTC Capture Allows for Detection of Heterogeneous Tumor Cell Populations APPLICATION OF CTC TECHNOLOGIES TO CLINICAL TESTING 153 CTC TECHNOLOGIES FOR CLINICAL DEVELOPMENT 154 Practical Application

9 TABLE 72 CTC ASSAY CLINICAL READINESS EVALUATION 155 TABLE 73 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS 156 STANDARD RECOMMENDATIONS 156 Specificity of a CTC Assay 157 Clinical Trial Design Considerations 158 TABLE 74 CTC QUALIFICATION STUDIES 158 SWOG S0500 Trial 159 Study Strategy and Process 159 CTC NUMBER AS A PROGNOSTIC BIOMARKER 161 Breast Cancer 161 Metastatic Castrate-resistant Prostate Cancer 161 Colorectal Cancer 162 Lung Cancer 162 PROGNOSTIC STUDIES 162 CTC'S AS A SURROGATE RESPONSE BIOMARKER 163 CTC'S AS A REAL-TIME BIOPSY 163 CTC CHIP TECHNOLOGY AND EGFR MUTATION ANALYSIS 164 CTC CHARACTERIZATION AFTER ENRICHMENT USING THE CELLSEARCH PLATFORM FINAL REMARKS CHAPTER 8 CIRCULATING TUMOR CELL MARKET 167 THE INVASIVE CANCER! 167 TABLE 75 GLOBAL CANCER INCIDENCE - ESTIMATES, (MILLIONS) 167 FIGURE 13 GLOBAL CANCER INCIDENCE - ESTIMATES, (MILLIONS) 167 CANCER SURVIVAL 168 TABLE 76 GLOBAL CANCER SURVIVORS, 2008 (MILLIONS) 169 FIGURE 14 GLOBAL CANCER SURVIVORS 2008 (MILLIONS) 169 TABLE 77 UNITED STATES CANCER SURVIVORS, (MILLIONS) 169 TABLE 78 MALE CANCER SURVIVORS (%) 170 TABLE 79 FEMALE CANCER SURVIVORS (%) 170 GLOBAL ANNUAL ONCOLOGY MARKET 171 CANCER THERAPY 172 TABLE 80 MAJOR PLAYERS 172 TABLE 81 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) FIGURE 15 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, ($ MILLIONS) AGING AND CANCER 174 CANCER DRUG PIPELINE 174 TABLE 82 DRUGS APPROVED IN CANCER COSTS IN THE U.S. 175 TABLE 83 CANCER FORECAST IN U.S., KEY FACTS 176 TABLE 84 CANCER CARE COST IN U.S., 2010 AND 2020 ($ BILLIONS) 177 BREAST CANCER 177 Treatment and Survival 177 Common Side Effects of Treatment 178 COLON AND RECTUM

10 Treatment and Survival 179 Common Side Effects of Treatment 179 PROSTATE 180 Treatment and Survival 180 Common Side Effects of Treatment 180 CHEMOTHERAPY MARKET 180 CANCER TESTING MARKET 181 TABLE 85 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST THROUGH 2018 ($ MILLIONS) FIGURE 16 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST ($ MILLIONS) TABLE 86 CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 183 FIGURE 17 CANCER TESTING MARKET AND FORECAST, ($ MILLIONS) 183 TABLE 87 KEY PLAYERS 184 IVD Market in China 185 CURRENT CANCER DIAGNOSTIC TESTS 186 Cancer Testing in Developing Nations 186 New Opportunities 186 TABLE 88 SIGNIFICANT DEVELOPMENTS IN CANCER FOLLOW-UP 187 A UNIVERSAL TUMOR TEST- IS IT POSSIBLE? 187 TABLE 89 CANCER TESTS AND LIMITATIONS - THE CASE AGAINST DEVELOPMENT OF A UNIVERSAL TEST CANCER BIOMARKER TESTING MARKET 188 TABLE 90 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) FIGURE 18 GLOBAL BIOMARKER MARKET AND FORECAST, ($ MILLIONS) 188 TABLE 91 THE KEY PLAYERS 189 TABLE 92 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) FIGURE 19 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, ($ MILLIONS) MOLECULAR DIAGNOSTICS 191 TABLE 93 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) FIGURE 20 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, ($ MILLIONS) CANCER BIOMARKER TESTS 192 CANCER DISEASE MANAGEMENT 192 PERSONALIZED CANCER TESTING 192 Cancer Testing Competitors 192 CIRCULATING TUMOR CELL MARKET - A NEW APPROACH 193 TABLE 94 CTC S - DIFFERENTIATING FEATURES 194 CTCs Advantages 194 THE CLINICAL DIAGNOSTICS MARKET 195 Market Opportunities 195 TABLE 95 STEM CELL MARKET OVERVIEW 196 TABLE 96 KEY COMPANIES SELLING STEM CELL RESEARCH PRODUCTS 196 CTC Testing 197 TABLE 97 CTC COMPANIES WITH PROMISING PRODUCTS

11 CellSearch CTC test 198 TABLE 98 CLINICAL USE OF CELLSEARCH SYSTEM 198 AdnaTest 198 CURRENT STATUS OF THE MARKET 198 TABLE 99 PRICING (DOLLARS) 199 TABLE 100 CELLSEARCH KIT 199 Updated Coding and Payment for Circulating Tumor Cell Testing 200 Global Market for Circulating Cancer Cells (CTCs) 200 TABLE 101 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) FIGURE 21 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, ($ MILLIONS) TABLE 102 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) FIGURE 22 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, ($ MILLIONS) TABLE 103 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) FIGURE 23 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, ($ MILLIONS) TABLE 104 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) FIGURE 24 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER -SALES AND FORECAST BY REGION, ($ MILLIONS) United States Market for Circulating Cancer Cells (CTCs) 206 TABLE 105 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) FIGURE 25 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, ($ MILLIONS) TIMELINE 207 TABLE 106 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION, SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) FIGURE 26 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION SALES AND FORECAST, ($ MILLIONS) Europe - Market for Circulating Cancer Cells (CTCs) 208 TABLE 107 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) FIGURE 27 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, ($ MILLIONS) TABLE 108 EUROPEAN CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) Rest of World Market for Circulating Cancer Cells (CTCs) 210 TABLE 109 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) FIGURE 28 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, ($ MILLIONS) Canada 211 TABLE 110 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) FIGURE 29 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, ($ MILLIONS)

12 ASIA-PACIFIC SOLID TUMORS MARKET 212 FUTURE AND NEXT STEPS 213 CHAPTER 9 PATENTS 216 TABLE 111 CIRCULATING TUMOR CELL ASSAY CHARACTERISTICS 216 KEY PATENTS 216 TABLE 112 CTC PATENTS 217 VERIDEX 218 EpCAM Based Enrichment Using Magnetic Beads 218 MAGSWEEPER 218 EpCAM Based Magnetic Beads 218 SCRIPPS RESEARCH INSTITUTE (EPIC SCIENCES) 219 HD-CTC Technology 219 CELLPOINT DIAGNOSTICS 219 ON-Q-ITY 219 BIOFLUIDICA 219 ADNAGEN 220 Multiple Antibodies on Magnetic Beads 220 FILTINI 220 3D Parylene Membrane Filter for Isolation of CTC 220 IKONISYS 220 AVIVA BIOSCIENCES 221 Methods, Compositions, and Automated Systems for Separating Rare Cells TABLE 113 KEY PATENTS BY AVIVA BIOSCIENCES 221 HARVARD UNIVERSITY - MEHMET TONER, PHD 221 Microposts Coated with EpCAM 221 CELLECTIVE DX 222 Materal Displacement Obstacle Chip 222 JOHNS HOPKINS UNIVERSITY 222 Antibody-Coated Microfluidic Chip and Quantum Dots-Based Imaging 222 MEDICAL DISCOVERY PARTNERS 222 RBC Agglutination Followed by Filtration 222 CYNVENIO BIOSYSTEMS 222 Microfluidic Sheath Flow for Cell Isolation 222 SCREENCELL 223 BIOCEPT 223 Recovery of Rare Cells Using a Microchannel Apparatus with Patterned Posts CANOPUS BIOSCIENCE 223 Enrichment Technology Is Now Protected by Key Patents 223 ADVANCED CELL DIAGNOSTICS CHAPTER 10 SELECTED COMPANY PROFILES 226 COMPANIES 226 KEY PLAYERS 226 TABLE 114 COMMERCIAL CIRCULATING TUMOR CELL TECHNOLOGY PLATFORMS 226 KEY COMPANY PROFILES 227

13 ADNAGEN 227 ADVANCED CELL DIAGNOSTICS 227 APOCELL 228 AVIVA BIOSCIENCES 228 BIOCEP LTD. 229 BIOCEPT INC. 229 BIOFLUIDICA MICROTECHNOLOGIES LLC 230 CANOPUS BIOSCIENCES 230 CELLTRAFIX INC. 230 CELULA 231 CLEARBRIDGE BIOMEDICS 231 CREATV MICROTECH INC 232 CYNVENIO BIOSYSTEMS, INC. 232 EPIC BIOSCIENCES 232 FILTINI INC. 233 FLUXION BIOSCIENCES 233 GREINER BIO-ONE GMBH 233 IKONISYS INC. 234 IVDIAGNOSTICS INC. 234 JANSSEN DIAGNOSTICS 234 MILTENYI BIOTECH 234 NANOSTRING TECHNOLOGIES INC. 235 NATURAL NANO INC. 235 ONCO VISTA 235 ON-Q-ITY 235 RARECELLS 236 SCREENCELL 236 SILICON BIOSYSTEMS USA 237 STEMCELL TECHNOLOGIES 237 SYNERGEX CORPORATION 237 SYSMEX CORPORATION 238 VERIDEX, LLC 238 VITATEX INC. 239 CHAPTER 11 REFERENCES 241

14 LIST OF TABLES TABLE HEADING SUMMARY TABLE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, THROUGH 2018 ($ MILLIONS) TABLE 1 CATEGORIES OF STEM CELLS 14 TABLE 2 PRODUCT CATEGORIES 15 TABLE 3 KEY FACTORS OF CTC S 16 TABLE 4 CIRCULATING TUMOR CELLS - FEATURES 18 TABLE 5 METASTATIC CASCADE 24 TABLE 6 EPCAM-BASED ASSAYS 26 TABLE 7 CTC DETECTION - ADVANTAGES 29 TABLE 8 CANCER - KEY FACTS 32 TABLE 9 CANCER CAUSES 33 TABLE 10 CANCER CAUSING FACTORS 34 TABLE 11 CANCER SCREENING METHODS 35 TABLE 12 NONCOMMUNICABLE DISEASES ACTION PLAN 36 TABLE 13 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS) 37 TABLE 14 ESTIMATED GLOBAL CANCER INCIDENCE, 2008 (THOUSANDS) 38 TABLE 15 INCREASE IN CANCER BURDEN - FACTORS 41 TABLE 16 THE MAIN TYPES OF CANCER AND ASSOCIATED MORTALITY 43 TABLE 17 GENERAL GLOBAL CANCER INCIDENCE BY TYPE 43 TABLE 18 GLOBAL INCIDENCE OF CANCER BY TYPE, 2008 (THOUSANDS/%) 44 TABLE 19 CANCER INCIDENCE IN MEN, 2008 (THOUSANDS/%) 45 TABLE 20 CANCER INCIDENCE IN WOMEN, 2008 (THOUSANDS/%) 46 TABLE 21 GLOBAL INCIDENCE OF CANCER IN DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000, 2008 TABLE 22 GLOBAL INCIDENCE OF CANCER IN MEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008 TABLE 23 GLOBAL INCIDENCE OF CANCER IN WOMEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008 TABLE 24 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, TABLE 25 GLOBAL BREAST CANCER FACTS 51 TABLE 26 BREAST CANCER IN THE UNITED STATES 52 TABLE 27 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN MEN, 2008 TABLE 28 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN WOMEN, 2008 TABLE 29 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, TABLE 30 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF PROSTATE CANCER, 2008 TABLE 31 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS) TABLE 32 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008 TABLE 33 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, TABLE 34 PROSTATE CANCER CASES AND DEATHS IN THE U.S TABLE 35 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., TABLE 36 PROSTATE CANCER INCIDENCE RATES IN THE U.S. BY RACE, (PER 100,000 MEN)

15 TABLE HEADING TABLE 37 ESTIMATED PROSTATE CANCER CASES IN THE U S., 2020 AND 2030 TABLE 38 MORTALITY RATES BY RACE IN U.S., TABLE 39 ESTIMATED PROSTATE CANCER IN CANADA, TABLE 40 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION, 2008 TABLE 41 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION) TABLE 42 POTENTIAL APPLICATIONS OF CTC-BASED DIAGNOSTICS 74 TABLE 43 CLINICAL RELEVANCE OF CTC 78 TABLE 44 CTC ENRICHMENT METHODS 78 TABLE 45 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ENRICHMENT 80 TABLE 46 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ANALYSIS 84 TABLE 47 ENUMERATION TECHNIQUES 86 TABLE 48 FUNCTIONAL ASSAYS 90 TABLE 49 KEY FACTS ABOUT CIRCULATING TUMOR CELLS 97 TABLE 50 MICRO-COUNT FEATURES A NEW TECHNOLOGY 98 TABLE 51 CTC ASSAY PRE-ANALYTICAL VALIDATION CONSIDERATIONS 102 TABLE 52 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS 102 TABLE 53 CTC ASSAY POST-ANALYTICAL VALIDATION CONSIDERATIONS 103 TABLE 54 CURRENT ENRICHMENT ASSAYS FOR CTCS 105 TABLE 55 CTC ENUMERATION ASSAYS 108 TABLE 56 CHARACTERIZATION ASSAYS FOR CTCS 111 TABLE 57 KEY FEATURES-IVD CTC TESTS 112 TABLE 58 TUMOR TYPES: PROJECTED NEW CASES AND ESTIMATED DEATHS, TABLE 59 PROSTATE CANCER DIAGNOSIS AND ROLE OF CTC'S 115 TABLE 60 CURRENT DIAGNOSTIC METHODS 115 TABLE 61 APOSTREAM KEY FEATURES 116 TABLE 62 CANOPUS BIOSCIENCE TECHNOLOGY - BENEFITS 118 TABLE 63 CELLOPTICS' CANCER APPLICATION 118 TABLE 64 CELLOPTICS' KEY FEATURES - ENRICHMENT 119 TABLE 65 CELLOPTICS' KEY FEATURES - LABELING 119 TABLE 66 CELLOPTICS' KEY FEATURES - DETECTION 120 TABLE 67 ISET TEST - SPECIFICATIONS 120 TABLE 68 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT 137 TABLE 69 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT 142 TABLE 70 EPISPOT: CLINICAL TRIALS FOR DETECTION OF CTC S 148 TABLE 71 OUTCOME MEASUREMENTS NCT TRIAL 149 TABLE 72 CTC ASSAY CLINICAL READINESS EVALUATION 155 TABLE 73 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS 156 TABLE 74 CTC QUALIFICATION STUDIES 158 TABLE 75 GLOBAL CANCER INCIDENCE - ESTIMATES, (MILLIONS) 167 TABLE 76 GLOBAL CANCER SURVIVORS, 2008 (MILLIONS) 169 TABLE 77 UNITED STATES CANCER SURVIVORS, (MILLIONS) 169 TABLE 78 MALE CANCER SURVIVORS (%) 170 TABLE 79 FEMALE CANCER SURVIVORS (%) 170 TABLE 80 MAJOR PLAYERS

16 TABLE HEADING TABLE 81 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) TABLE 82 DRUGS APPROVED IN TABLE 83 CANCER FORECAST IN U.S., KEY FACTS 176 TABLE 84 CANCER CARE COST IN U.S., 2010 AND 2020 ($ BILLIONS) 177 TABLE 85 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST THROUGH 2018 ($ MILLIONS) TABLE 86 CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 183 TABLE 87 KEY PLAYERS 184 TABLE 88 SIGNIFICANT DEVELOPMENTS IN CANCER FOLLOW-UP 187 TABLE 89 CANCER TESTS AND LIMITATIONS - THE CASE AGAINST DEVELOPMENT OF A UNIVERSAL TEST TABLE 90 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) TABLE 91 THE KEY PLAYERS 189 TABLE 92 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) TABLE 93 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) TABLE 94 CTC S - DIFFERENTIATING FEATURES 194 TABLE 95 STEM CELL MARKET OVERVIEW 196 TABLE 96 KEY COMPANIES SELLING STEM CELL RESEARCH PRODUCTS 196 TABLE 97 CTC COMPANIES WITH PROMISING PRODUCTS 197 TABLE 98 CLINICAL USE OF CELLSEARCH SYSTEM 198 TABLE 99 PRICING (DOLLARS) 199 TABLE 100 CELLSEARCH KIT 199 TABLE 101 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) TABLE 102 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) TABLE 103 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) TABLE 104 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) TABLE 105 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) TABLE 106 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION, SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) TABLE 107 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) TABLE 108 EUROPEAN CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) TABLE 109 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) TABLE 110 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) TABLE 111 CIRCULATING TUMOR CELL ASSAY CHARACTERISTICS 216 TABLE 112 CTC PATENTS 217 TABLE 113 KEY PATENTS BY AVIVA BIOSCIENCES 221 TABLE 114 COMMERCIAL CIRCULATING TUMOR CELL TECHNOLOGY PLATFORMS

17 LIST OF FIGURES FIGURE TITLE SUMMARY FIGURE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, ($ MILLIONS) FIGURE 1 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS) 37 FIGURE 2 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, FIGURE 3 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, FIGURE 4 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS) FIGURE 5 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008 FIGURE 6 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER FIGURE 7 PROSTATE CANCER CASES AND DEATHS IN THE U.S., FIGURE 8 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., FIGURE 9 ESTIMATED PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030 FIGURE 10 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008 FIGURE 11 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION) FIGURE 12 TUMOR TYPES - PROJECTED NEW CASES AND ESTIMATED DEATHS, FIGURE 13 GLOBAL CANCER INCIDENCE - ESTIMATES, (MILLIONS) 167 FIGURE 14 GLOBAL CANCER SURVIVORS 2008 (MILLIONS) 169 FIGURE 15 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, ($ MILLIONS) FIGURE 16 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST ($ MILLIONS) FIGURE 17 CANCER TESTING MARKET AND FORECAST, ($ MILLIONS) 183 FIGURE 18 GLOBAL BIOMARKER MARKET AND FORECAST, ($ MILLIONS) 188 FIGURE 19 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, ($ MILLIONS) FIGURE 20 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, ($ MILLIONS) FIGURE 21 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, ($ MILLIONS) FIGURE 22 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, ($ MILLIONS) FIGURE 23 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, ($ MILLIONS) FIGURE 24 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER -SALES AND FORECAST BY REGION, ($ MILLIONS) FIGURE 25 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, ($ MILLIONS) FIGURE 26 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION SALES AND FORECAST, ($ MILLIONS) FIGURE 27 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, ($ MILLIONS) FIGURE 28 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, ($ MILLIONS)

18 FIGURE TITLE FIGURE 29 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, ($ MILLIONS) 212

Circulating Tumor Cells (CTC) Technologies

Circulating Tumor Cells (CTC) Technologies Table of Contents MIR036 I. SCOPE AND METHODOLOGY Scope of the Study Analytics and data presented in this report pertain to several parameters such as - Research Methodology This report is uniquely researched

More information

LIQUID BIOPSY RESEARCH TOOLS, SERVICES AND DIAGNOSTICS: GLOBAL MARKETS

LIQUID BIOPSY RESEARCH TOOLS, SERVICES AND DIAGNOSTICS: GLOBAL MARKETS LIQUID BIOPSY RESEARCH TOOLS, SERVICES AND DIAGNOSTICS: GLOBAL MARKETS BIO150A January 2016 John Bergin Project Analyst ISBN: 1-62296-224-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA

More information

MARCH 2017 RESEARCH REPORT

MARCH 2017 RESEARCH REPORT 1 MARCH 2017 RESEARCH REPORT LIQUID BIOPSY MARKETS by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides Liquid Biopsy

More information

GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst

GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,

More information

Challenges for use of CTCs as a Diagnostic. Farideh Z. Bischoff, Ph.D. Interim CSO Sr. Director, Translational Clinical Development Biocept, Inc.

Challenges for use of CTCs as a Diagnostic. Farideh Z. Bischoff, Ph.D. Interim CSO Sr. Director, Translational Clinical Development Biocept, Inc. Challenges for use of CTCs as a Diagnostic Farideh Z. ischoff, Ph.D. Interim CSO Sr. Director, Translational Clinical Development iocept, Inc. Current Technology for CTC Testing Existing CTC testing platform

More information

High Sensitivity Immunomagnetic CTC Isolation as Compared to Alternative Isolation Methods

High Sensitivity Immunomagnetic CTC Isolation as Compared to Alternative Isolation Methods High Sensitivity Immunomagnetic CTC Isolation as Compared to Alternative Isolation Methods 1. Introduction: An overview of CTC isolation methods 2. Challenges for direct comparisons of CTC recovery 3.

More information

MAGNETIC ISOLATION AND MOLECULAR ANALYSIS OF SINGLE CIRCULATING AND DISSEMINATED TUMOR CELLS ON CHIP

MAGNETIC ISOLATION AND MOLECULAR ANALYSIS OF SINGLE CIRCULATING AND DISSEMINATED TUMOR CELLS ON CHIP MAGNETIC ISOLATION AND MOLECULAR ANALYSIS OF SINGLE CIRCULATING AND DISSEMINATED TUMOR CELLS ON CHIP CRISTINA DE JONCHEERE LIESBET LAGAE, TIM STAKENBORG, CHENGXUN LIU MIRACLE (FP7 257743) OVERVIEW Miracle

More information

CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS

CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS PHM173A January 2015 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-008-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

BIOPSY DEVICES: TECHNOLOGY AND GLOBAL MARKETS

BIOPSY DEVICES: TECHNOLOGY AND GLOBAL MARKETS BIOPSY DEVICES: TECHNOLOGY AND GLOBAL MARKETS HLC171B March 2016 Yojana Jeevane Project Analyst ISBN: 1-62296-257-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

A Novel CTC-Detecting Technique Using TelomeScan and Its Clinical Applications

A Novel CTC-Detecting Technique Using TelomeScan and Its Clinical Applications A Novel CTC-Detecting Technique Using TelomeScan and Its Clinical Applications Yasuo Urata CEO and President Oncolys BioPharma Inc. February 16, 2013 Telomere Length is a Limiting Factor for Cell Replication

More information

Colorectal cancer diagnostics: biomarkers, cellfree DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis

Colorectal cancer diagnostics: biomarkers, cellfree DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis Expert Review of Molecular Diagnostics ISSN: 1473-7159 (Print) 1744-8352 (Online) Journal homepage: http://www.tandfonline.com/loi/iero20 Colorectal cancer diagnostics: biomarkers, cellfree DNA, circulating

More information

Survey Results Q1. How would you best describe your organization?

Survey Results Q1. How would you best describe your organization? Survey Results Q1. How would you best describe your organization? Q2. How high would you rate the priority of Circulating Tumor Cells in you organization? Q3. What do you think is the biggest challenge

More information

The Presence and Persistence of Resistant and Stem Cell- Like Tumor Cells as a Major Problem in Ovarian Cancer

The Presence and Persistence of Resistant and Stem Cell- Like Tumor Cells as a Major Problem in Ovarian Cancer Welcome! The Presence and Persistence of Resistant and Stem Cell- Like Tumor Cells as a Major Problem in Ovarian Cancer Prof. Sabine Kasimir-Bauer Department of Gynecology and Obstetrics University Hospital

More information

ORGANIC FOODS AND BEVERAGES: GLOBAL MARKETS

ORGANIC FOODS AND BEVERAGES: GLOBAL MARKETS ORGANIC FOODS AND BEVERAGES: GLOBAL MARKETS FOD067A June 2014 Natraj Pandal Project Analyst ISBN: 1-56965-851-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within

More information

MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:

MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN: MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS PHM154A September 2013 Anand Gijare Project Analyst ISBN: 1-56965-544-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301

More information

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and

More information

CTC in clinical studies: Latest reports on GI cancers

CTC in clinical studies: Latest reports on GI cancers CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis

More information

RENAL BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

RENAL BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS RENAL BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS BIO138A January 2015 Cheng-Yuk Lee Project Analyst ISBN: 1-62296-003-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 024 USA 866-285-7215 (toll-free

More information

Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego

Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego National Cancer Institute, Slovakia Translational Research Unit Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer Michal Mego 2 nd Department of Oncology, Faculty

More information

NUTRACEUTICALS: GLOBAL MARKETS

NUTRACEUTICALS: GLOBAL MARKETS NUTRACEUTICALS: GLOBAL MARKETS FOD013E November 2014 Natraj Pandal Project Analyst ISBN: 1-56965-992-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the

More information

INTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS

INTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS HLC046C November 2014 Mary C. Patton Project Analyst ISBN: 1-56965-982-6 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

Liquid Biopsy: Implications for Cancer Staging & Therapy

Liquid Biopsy: Implications for Cancer Staging & Therapy Prof. Klaus Pantel, MD, PhD Institut für Tumorbiologie Liquid Biopsy: Implications for Cancer Staging & Therapy Tumor cell dissemination and cancer dormancy Primary tumor Local relapse Cancer cells disseminate

More information

DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS

DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS BIO067B July 2014 Jon Evans Project Analyst ISBN: 1-56965-883-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within

More information

Circulating tumor cells/dna/etc for Radiation Oncologists

Circulating tumor cells/dna/etc for Radiation Oncologists Circulating tumor cells/dna/etc for Radiation Oncologists Andrew Z. Wang, M.D. Associate Professor Director of Clinical and Translational Research Department of Radiation Oncology Carolina Center for Cancer

More information

Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast

Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market

More information

THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER. HLC143A June Usha Nagavarapu Project Analyst ISBN: X

THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER. HLC143A June Usha Nagavarapu Project Analyst ISBN: X THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER HLC143A June 2013 Usha Nagavarapu Project Analyst ISBN: 1-56965-431-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301

More information

Prospective Clinical Study of Circulating Tumor Cells For Colorectal Cancer Screening

Prospective Clinical Study of Circulating Tumor Cells For Colorectal Cancer Screening Prospective Clinical Study of Circulating Tumor Cells For Colorectal Cancer Screening Results From a Multi-Year 620-Sample Study CRC: SLOW GROWING, PREVENTABLE POLYP TO CANCER CAN TAKE 5 TO 15 YEARS CANCER

More information

Circulating tumor cells

Circulating tumor cells Circulating tumor cells counts and characteristics Bianca Mostert Circulating tumor cells counts and characteristics Bianca Mostert The studies described in this thesis were performed at the Department

More information

METACELL. PERSONALIZED CANCER THERAPY USING CIRCULATING TUMOR CELLS (CTCs) METACELL LIQUID BIOPSY

METACELL. PERSONALIZED CANCER THERAPY USING CIRCULATING TUMOR CELLS (CTCs) METACELL LIQUID BIOPSY METACELL PERSONALIZED CANCER THERAPY USING CIRCULATING TUMOR CELLS (s) AN EASY WAY TO LIQUID BIOPSY MORE THAN A METASTATIC CELL IN BLOOD A STEP TOWARDS PERSONALIZED CANCER TREATMENT LIQUID BIOPSY REAL-TIME

More information

Clinical Liquid Biopsy Explained: Applications, Techniques and Players

Clinical Liquid Biopsy Explained: Applications, Techniques and Players Volume XX, Issue 3 Clinical Liquid Biopsy Explained: Applications, Techniques and Players A minimally invasive diagnostic that can help clinicians detect, diagnose and manage cancer patients has long been

More information

La biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro

La biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity

More information

WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE 1 CANCER PATIENTS

WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE 1 CANCER PATIENTS WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE 1 CANCER PATIENTS There is uncertainty whether their prognosis will improve It can take as long as 3 months to learn

More information

INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS

INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA

More information

RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS

RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS HLC176A February 2015 Neha Maliwal Project Analyst ISBN: 1-62296-043-2 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

1/23/2017. Alarice Lowe, MD Assistant Professor of Pathology Director, Circulating Tumor Cell Lab Brigham and Women s Hospital Harvard Medical School

1/23/2017. Alarice Lowe, MD Assistant Professor of Pathology Director, Circulating Tumor Cell Lab Brigham and Women s Hospital Harvard Medical School Application of Cytologic Techniques to Circulating Tumor Cell Specimens Alarice Lowe, MD Assistant Professor of Pathology Director, Circulating Tumor Cell Lab Brigham and Women s Hospital Harvard Medical

More information

THERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE

THERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE THERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE PHM125A January 2013 Willem Westra Project Analyst ISBN: 0-89336-715-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215,

More information

JAK AND PI3K SIGNALING PATHWAY MARKETS

JAK AND PI3K SIGNALING PATHWAY MARKETS JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-793-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

Review. Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis capable malignancy.

Review. Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis capable malignancy. For reprint orders, please contact: reprints@futuremedicine.com Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis capable malignancy Patrizia Paterlini-Bréchot

More information

Inertia based microfluidic capture and characterisation of circulating tumour cells for the diagnosis of lung cancer

Inertia based microfluidic capture and characterisation of circulating tumour cells for the diagnosis of lung cancer Original Article Page 1 of 6 Inertia based microfluidic capture and characterisation of circulating tumour cells for the diagnosis of lung cancer Dimple Y. Chudasama 1,2,3, Daria V. Freydina 1,4, Maxim

More information

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( ) Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United

More information

U.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE

U.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE U.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE FOD029E January 2015 Mary Anne Crandall Project Analyst ISBN: 1-62296-005-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE CANCER PATIENTS

WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE CANCER PATIENTS WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE CANCER PATIENTS There is uncertainty whether their prognosis will improve It can take as long as 3 months to learn

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage

Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,

More information

Youngnam Cho. National Cancer Center Biomarker Branch

Youngnam Cho. National Cancer Center Biomarker Branch Youngnam Cho National Cancer Center Biomarker Branch Contents 1. Liquid Biopsy 2. Circulating Tumor Cells from Blood 3. Cell-free DNA from Blood 1. Liquid biopsy Cancer Diagnosis IMAGING TISSUE BIOPSY

More information

Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022

Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022 Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022 By Value (In Million USD) By Volume (In Million Units)

More information

Country Coverage. Company Coverage

Country Coverage. Company Coverage Global Heart Valve Devices Market: Analysis By Procedure (Replacement & Repair), Replacement Procedure By Technique (Mechanical, Bioprosthetic & TAVR), Repair Procedure By Technique (Surgical, Balloon

More information

Detection of the Circulating Tumor Cells in Cancer Patients

Detection of the Circulating Tumor Cells in Cancer Patients Detection of the Circulating Tumor Cells in Cancer Patients Athanasios Armakolas; Zacharoula Panteleakou; Adrianos Nezos; Aikaterini Tsouma; Maria Skondra; Peter Lembessis; Nikolaos Pissimissis; Michael

More information

AdnaNews. News from the meeting on Advances in Circulating Tumor Cells (ACTC), Reythymnon, Crete, Greece October 8-11, 2014.

AdnaNews. News from the meeting on Advances in Circulating Tumor Cells (ACTC), Reythymnon, Crete, Greece October 8-11, 2014. News from the meeting on Advances in Circulating Tumor Cells (ACTC), Reythymnon, Crete, Greece October 8-11, 2014. The ACTC meeting (www.actc2014.org) is together with the ISMRC meeting one of the most

More information

Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia (CML) Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is

More information

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW... CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A Local Coverage Determination (LCD): Circulating Tumor Cell Marker Assays (L35096) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information

More information

Accelerate Your Research with Conversant Bio

Accelerate Your Research with Conversant Bio Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely

More information

The Avatar System TM Yields Biologically Relevant Results

The Avatar System TM Yields Biologically Relevant Results Application Note The Avatar System TM Yields Biologically Relevant Results Liquid biopsies stand to revolutionize the cancer field, enabling early detection and noninvasive monitoring of tumors. In the

More information

Global Coverage. Regional Coverage. Company Coverage. Country Coverage. Global Coverage Regional Coverage Country Coverage

Global Coverage. Regional Coverage. Company Coverage. Country Coverage. Global Coverage Regional Coverage Country Coverage Global Influenza Drugs and Vaccines Market By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent): Analysis By Region, By Country: Opportunities and Forecast (2016-2021)

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

Page: 1 of 10. Detection of Circulating Tumor Cells in the Management of Patients with Cancer

Page: 1 of 10. Detection of Circulating Tumor Cells in the Management of Patients with Cancer Last Review Status/Date: September 2014 Page: 1 of 10 Management of Patients with Cancer Description The prognosis of cancer patients is often determined by the occurrence of metastatic disease. Studies

More information

In Situ Hybridization: Market Strategies and Forecasts, US,

In Situ Hybridization: Market Strategies and Forecasts, US, In Situ Hybridization: Market Strategies and Forecasts, US, 2018-2024 Table of Contents In Situ Hybridization: Executive Summary The study is designed to give a comprehensive overview of the In Situ Hybridization

More information

Molecular Diagnostic Solutions for Urologic Cancer

Molecular Diagnostic Solutions for Urologic Cancer 1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This

More information

Pancreatic Cancer Market Research Report- Global Forecast till 2023

Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report Information More information from: https://www.marketresearchfuture.com/reports/1638 Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report / Search Code: MRFR/HC/1107-HCRR Publish

More information

MICROELECTRONIC MEDICAL IMPLANTS: PRODUCTS, TECHNOLOGIES & OPPORTUNITIES

MICROELECTRONIC MEDICAL IMPLANTS: PRODUCTS, TECHNOLOGIES & OPPORTUNITIES MICROELECTRONIC MEDICAL IMPLANTS: PRODUCTS, TECHNOLOGIES & OPPORTUNITIES HLC016E May 2016 Andrew McWilliams Project Analyst ISBN: 1-62296-295-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

Circulating Stromal Cells in Immunotherapy Utilizing a Total Blood Based Biopsy

Circulating Stromal Cells in Immunotherapy Utilizing a Total Blood Based Biopsy Circulating Stromal Cells in Immunotherapy Utilizing a Total Blood Based Biopsy Cancer associated macrophage CTCs Daniel Adams Senior Research Scientist/Head of Clinical Core Laboratory Creatv MicroTech,

More information

Global Stevia Extracts Market Analysis By Type (Dried, Leaves, Powder, Liquid), Application, Region, Country: Opportunities and Forecast ( )

Global Stevia Extracts Market Analysis By Type (Dried, Leaves, Powder, Liquid), Application, Region, Country: Opportunities and Forecast ( ) Global Stevia Extracts Market Analysis By Type (Dried, Leaves, Powder, Liquid), Application, Region, Country: Opportunities and Forecast (2017-2022) Analysis By Type - Fresh/Dried leaves, Stevia powder,

More information

Disruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017

Disruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017 Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From

More information

Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023

Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023 Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023 Global Psoriasis Pipeline Drugs Industry Sizing, Growth and Forecast

More information

FISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC

FISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have

More information

REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif

More information

MEDICAL ULTRASOUND DEVICES: TECHNOLOGIES AND GLOBAL MARKETS

MEDICAL ULTRASOUND DEVICES: TECHNOLOGIES AND GLOBAL MARKETS MEDICAL ULTRASOUND DEVICES: TECHNOLOGIES AND GLOBAL MARKETS IAS040B October 2016 Paul Taylor Project Analyst ISBN: 1-62296-372-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) Executive Summary Tarceva (erlotinib): Key Metrics in NSCLC Markets 2012 Tarceva Sales US 5EU Japan China India

More information

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology

More information

Global Transcatheter Mitral Valve Repair and Replacement (TMVR) Market: Analysis By Region, By Country: Opportunities and Forecast ( )

Global Transcatheter Mitral Valve Repair and Replacement (TMVR) Market: Analysis By Region, By Country: Opportunities and Forecast ( ) Global Transcatheter Mitral Valve Repair and Replacement (TMVR) Market: Analysis By Region, By Country: Opportunities and Forecast (2017-2022) By Region- North America, Europe, APAC and RoW By Country

More information

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012

More information

Circulating and Disseminated Tumor Cells in the Management of Breast Cancer

Circulating and Disseminated Tumor Cells in the Management of Breast Cancer Anatomic Pathology / CTCs and DTCs in Breast Cancer Management Circulating and Disseminated Tumor Cells in the Management of Breast Cancer Jeffrey S. Ross, MD, and Elzbieta A. Slodkowska, MD Key Words:

More information

The CellCollector TM technology

The CellCollector TM technology The CellCollector TM technology In vivo isolation of circulating tumor cells by the CellCollector TM system Dr. Klaus Lücke (CEO) Unmet medical need in oncology: Access to tumor cells not only at the time

More information

The potential for liquid biopsies in the precision medical treatment of breast cancer

The potential for liquid biopsies in the precision medical treatment of breast cancer Cancer Biol Med 2016. doi: 10.28092/j.issn.2095-3941.2016.0007 REVIEW The potential for liquid biopsies in the precision medical treatment of breast cancer Victoria A. Forte 1,2, Dany K. Barrak 2,3, Mostafa

More information

ANESTHESIA AND RESPIRATORY DEVICES: GLOBAL MARKETS. HLC167A February Vijay Laxmi Project Analyst ISBN:

ANESTHESIA AND RESPIRATORY DEVICES: GLOBAL MARKETS. HLC167A February Vijay Laxmi Project Analyst ISBN: ANESTHESIA AND RESPIRATORY DEVICES: GLOBAL MARKETS HLC167A February 2014 Vijay Laxmi Project Analyst ISBN: 1-56965-704-1 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301

More information

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m

More information

Implantable Defibrillators Market by Product Type [Transvenous Implantable Cardioverter-Defibrillator (T-ICDs), Subcutaneous Implantable Cardioverter

Implantable Defibrillators Market by Product Type [Transvenous Implantable Cardioverter-Defibrillator (T-ICDs), Subcutaneous Implantable Cardioverter Implantable Defibrillators Market by Product Type [Transvenous Implantable Cardioverter-Defibrillator (T-ICDs), Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS), and Cardiac Resynchronization

More information

Global Radiation Therapy Market Report

Global Radiation Therapy Market Report Global Radiation Therapy Market Report ----------------------------------------- 2013 Executive Summary Radiotherapy is used to kill cancerous cells and is commonly used either alone or in combination

More information

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

Developing & Commercializing Targeted Small Molecule Drugs in Cancer Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

Thor Nilsen NeoGeneStar LLC January 22, 2015

Thor Nilsen NeoGeneStar LLC January 22, 2015 Thor Nilsen NeoGeneStar LLC January 22, 2015 NeoGeneStar TM I. Liquid biopsy using circulating cell-free DNA: Cancer diagnostics Prenatal diagnostics Other disease states II. NeoGeneStar TM cell-free DNA

More information

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical

More information

Opportunities and Challenges in the Development of Companion Diagnostics

Opportunities and Challenges in the Development of Companion Diagnostics Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine

More information

Global Remote Cardiac Monitoring Market: Size, Trends & Forecasts ( )

Global Remote Cardiac Monitoring Market: Size, Trends & Forecasts ( ) Global Remote Cardiac Monitoring Market: Size, Trends & Forecasts (2016-2020) #910680 $800 55 pages In Stock Report Description Scope of the Report The report entitled Global Remote Cardiac Monitoring

More information

Ultrasound Device Market - Industry Analysis, Size, Share, Growth and Forecasts to Hexa Research

Ultrasound Device Market - Industry Analysis, Size, Share, Growth and Forecasts to Hexa Research Ultrasound Device Market - Industry Analysis, Size, Share, Growth and Forecasts to 2024 - Hexa Research " The global ultrasound device market was valued at approximately USD 6.8 billion and it is projected

More information

Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy

Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com

More information

Myriad Genetics Corporate Presentation 6/4/13

Myriad Genetics Corporate Presentation 6/4/13 Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events

More information

DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA

DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA Maria Chimonidou 1, Areti Strati 1, Nikos Malamos 2, Vasilis Georgoulias

More information

Detecting Oncogenic Mutations in Whole Blood

Detecting Oncogenic Mutations in Whole Blood WHITE PAPER Detecting Oncogenic Mutations in Whole Blood Analytical validation of Cynvenio Biosystems LiquidBiopsy circulating tumor cell (CTC) capture and next-generation sequencing (NGS) September 2013

More information

REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) Executive Summary Xalkori (crizotinib): Key Metrics in NSCLC Markets 2012 Xalkori Sales US 5EU Japan China India

More information

Intracranial Pressure (ICP) Monitoring Market Research Report- Forecast to 2024

Intracranial Pressure (ICP) Monitoring Market Research Report- Forecast to 2024 Report Information More information from: https://www.marketresearchfuture.com/reports/703 Intracranial Pressure (ICP) Monitoring Market Research Report- Forecast to 2024 Report / Search Code: MRFR/HC/0232-CRR

More information

REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - Executive Summary The table below presents the key metrics for Kadcyla for human epidermal growth factor

More information

Cover Letter. Reviewer 1:

Cover Letter. Reviewer 1: Cover Letter Michael Yang, M.D., Ph.D. Managing Editor of Cancer Research Frontiers 1188 Willis Ave, #109, Albertson, NY 11507, USA Phone: +1-917-426-1571 http://cancer-research-frontiers.org/ Dear Dr.

More information

WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE1 CANCER PATIENTS

WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE1 CANCER PATIENTS WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE1 CANCER PATIENTS There is uncertainty whether their prognosis will improve It can take as long as 3 months to learn

More information

BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS

BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS BIO022G August 2015 Kim Lawson Project Analyst ISBN: 1-62296-134-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

Corporate Overview June NASDAQ: BIOC

Corporate Overview June NASDAQ: BIOC Corporate Overview June 2017 NASDAQ: BIOC www.biocept.com Forward-Looking Statements This presentation contains, and any accompanying oral presentation would no doubt contain, forward-looking statements,

More information

GLOBAL GENETIC TESTING MARKET. Growth Trends & Forecasts. mordorintelligence.com

GLOBAL GENETIC TESTING MARKET. Growth Trends & Forecasts. mordorintelligence.com GLOBAL GENETIC TESTING MARKET 2014-2020 Growth Trends & Forecasts mordorintelligence.com TABLE OF CONTENTS 1 Introduction 1.1 Report Description 1.2 Research Methodology 2. Genetic Testing Market Overview

More information

RD-100i OSNA the new generation of sentinel lymph node analysis in breast cancer

RD-100i OSNA the new generation of sentinel lymph node analysis in breast cancer RD-1i OSNA the new generation of sentinel lymph node analysis in breast cancer www.sysmex-europe.com RD-1i OSNA the new generation of sentinel lymph node analysis in breast cancer Sentinel node biopsy

More information

EPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets

EPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets EPIDEMIOLOGY Accurate, in-depth information for understanding and assessing targeted markets WHY ACCURATE MARKET FORECASTS Start with accurate understanding Epidemiology is the study of disease patterns

More information